ScoreOncology

Khorana score (chemotherapy-associated VTE)

Estimates the risk of venous thromboembolism in outpatients starting chemotherapy.

Updated 30 October 2026

When to use it

Before starting systemic chemotherapy in an outpatient with cancer, to consider primary thromboprophylaxis.

What it needs

  • Primary tumour siteOptions: Stomach or pancreas · Lung, lymphoma, gynaecological, bladder or testis · Other site
  • Pre-chemotherapy platelets ≥ 350 × 10⁹/LYes or no
  • Haemoglobin < 10 g/dL or use of erythropoiesis-stimulating agentsYes or no
  • Pre-chemotherapy leukocytes > 11 × 10⁹/LYes or no
  • BMI ≥ 35 kg/m²Yes or no

The points for each answer and the automatic total are in the app.

How to interpret it

Khorana score
ResultInterpretation
≤ 0Low risk (VTE ≈ 0.3–0.8 %)
1–2Intermediate risk (VTE ≈ 1.8–2 %)
≥ 3High risk (VTE ≈ 6.7–7.1 %)

Practical tip

ASCO guidelines suggest offering apixaban, rivaroxaban or LMWH with a score ≥ 2 if bleeding risk is low.

2 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top